6-(1-methylpyrrolidin-3-yloxy)-2H-isoquinolin-1-one | 1036069-82-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 6-(1-methylpyrrolidin-3-yloxy)-2H-isoquinolin-1-one
• 英文别名: 6-(1-methylpyrrolidin-3-yl)oxy-2H-isoquinolin-1-one
• CAS: 1036069-82-5
• 化学式: C₁₄H₁₆N₂O₂
• 分子量: 244.293
• InChiKey: ZNIGGVRFEDVIOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Isoquinoline derivatives
  申请人：Ray Christopher Peter

  公开号：US20070135479A1

  公开（公告）日：2007-06-14

  The invention relates to isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH 2 ; m is 0, 1 or 2; n is 1 or 2; R 1 is H, when Y is NH 2 ; or R. is H, (C 1-4 )alkyl or halogen, when Y is OH; R 2 and R 3 are independently H, (C 1-4 )alkyl or halogen; R is H or (C 1-6 )alkyl, optionally substituted with OH, (C 1-4 )-alkyloxy, (C 1-4 )alkyloxycarbonyl, (C 3-7 )cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C 6-10 )aryl, (C 6-10 )aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C 1-4 )alkyl, (C 1-4 )alkyloxy, (C 1-4 )alkylsulfonyl and halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of the isoquinoline derivatives in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.

  本发明涉及具有通式I的异喹啉衍生物，其中X为O、S或NH；Y为OH或NH2；m为0、1或2；n为1或2；当Y为NH2时，R1为H；或当Y为OH时，R为H、(C1-4)烷基或卤素；R2和R3独立地为H、(C1-4)烷基或卤素；R为H或(C1-6)烷基，可选地取代为OH、(C1-4)烷氧基、(C1-4)烷氧羰基、(C3-7)环烷基，可选地包含从O和S中选择的杂原子，(C6-10)芳基、(C6-10)芳氧基或包含1-3个从O、N和S中独立选择的杂原子的5-或6成员杂芳基，每个芳基或杂芳基可选地取代为1-3个从(C1-4)烷基、(C1-4)烷氧基、(C1-4)烷基磺酰基和卤素中独立选择的取代基；或其药学上可接受的盐，以及包含相同的药物组合物，以及在治疗ROCK-I相关疾病如高血压、动脉粥样硬化和青光眼中使用异喹啉衍生物。
• Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase
  申请人：PLETTENBURG Oliver

  公开号：US20100063025A1

  公开（公告）日：2010-03-11

  The invention relates to 6-substituted isoquinoline and isochinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

  该发明涉及公式（I）的6-取代异喹啉和异喹啉衍生物，可用于治疗和/或预防与Rho-激酶和/或Rho-激酶介导的肌球蛋白轻链磷酸酶磷酸化相关的疾病，并且含有这些化合物的组合物。
• SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES
  申请人：Plettenburg Oliver

  公开号：US20120316152A1

  公开（公告）日：2012-12-13

  A method for the treatment or prevention in a mammal of a disease associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase comprising administering to the mammal in need thereof at least one compound of the formula (I)

  一种用于治疗或预防哺乳动物中与Rho-激酶和/或Rho-激酶介导的肌球蛋白轻链磷酸酶磷酸化相关的疾病的方法，包括向需要该方法的哺乳动物中至少给予一个式(I)的化合物。
• ISOQUINOLINE DERIVATIVES
  申请人：N.V. Organon

  公开号：EP1963304B1

  公开（公告）日：2009-06-24
• SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE
  申请人：Sanofi-Aventis

  公开号：EP2102187A1

  公开（公告）日：2009-09-23